ReviewMolecular psychiatry2026
Revolutionizing MDD diagnosis: the integrated role of circRNAs and biosensor technology.
Review in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major Depressive Disorder (MDD) is a globally widespread mental health disorder that frequently remains underdiagnosed and inadequately treated. Recent advancements in circular RNAs (circRNAs) have illuminated their potential as biomarkers for a variety of diseases, including MDD. This review emphasizes the advantages of circRNA enrichment methodologies over traditional techniques, particularly isotachophoresis. Furthermore, the intricate role of circRNAs in the pathophysiological processes underlying MDD, as well as their integration with biosensor technology to improve diagnostic accuracy and efficiency, are synthesised. However, the clinical translation of circRNA-based diagnostics faces significant challenges, including the low abundance of circRNAs in bodily fluids, the need for highly sensitive and rapid detection platforms, and the lack of standardized, point-of-care compatible methods. A comprehensive overview of current circRNA detection methods, delineating their similarities and differences, is discussed. Insights for the anticipated advancements in quantitative and rapid circRNA detection is proposed. This review not only presents a thorough assessment of emerging trends in circRNA detection but also elaborates on primary techniques, traditional approaches, and recent innovations within the field of biosensor-based MDD diagnostics.
Indexed as
Identifiers
42120555What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.